EUVIMEDEUVIMED entdecken
Open Access

Pyroptosis Induction with Nanosonosensitizer‐Augmented Sonodynamic Therapy Combined with PD‐L1 Blockade Boosts Efficacy against Liver Cancer

Nisi Zhang, Wenlong Zeng, Yunxue Xu, Rui Li, Mengxuan Wang, Yijia Liu, Shuai Qu, Katherine W Ferrara, Zhifei Dai iD

Advanced Healthcare Materials · 2024-03 · 13 (7)

DOI: 10.1002/adhm.202302606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 28.11.2023. Verfasst von Nisi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, Peking University, Beijing, 100871, P. R. Chi…. Hauptthemen laut MEDLINE: Liver Neoplasms, Ultrasonic Therapy, Nanoparticles. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Induction of pyroptosis can promote anti‐PD‐L1 therapeutic efficacy due to the release of pro‐inflammatory cytokines, but current approaches can cause off target toxicity. Herein, a phthalocyanine‐conjugated mesoporous silicate nanoparticle (PMSN) is designed for amplifying sonodynamic therapy (SDT) to augment oxidative stress and induce robust pyroptosis in tumors. The sub‐10 nm diameter structure and c(RGDyC)‐PEGylated modification enhance tumor targeting and renal clearance. The unique porous architecture of PMSN doubles ROS yield and enhances pyroptotic cell populations in tumors (25.0%) via a cavitation effect. PMSN‐mediated SDT treatment efficiently reduces tumor mass and suppressed residual tumors in treated and distant sites by synergizing with PD‐L1 blockade (85.93% and 77.09%, respectively). Furthermore, loading the chemotherapeutic, doxorubicin, into PMSN intensifies SDT‐pyroptotic effects and increased efficacy. This is the first report of the use of SDT regimens to induce pyroptosis in liver cancer. This noninvasive and effective strategy has potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsUltrasonic TherapyNanoparticlesHumansPyroptosisB7-H1 AntigenCell Line, TumorImmunotherapy

Stichwörter der Autor:innen

immunotherapyliver cancerpyroptosissilicate nanoparticlessonodynamic therapy

Substanzen

B7-H1 Antigen

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, Peking University, Beijing, 100871, P. R. China.
  • Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.

ORCID-Profile: Zhifei Dai

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Zhang, N., Zeng, W., Xu, Y., Li, R., Wang, M., Liu, Y., Qu, S., Ferrara, K. W., & Dai, Z. (2024). Pyroptosis Induction with Nanosonosensitizer‐Augmented Sonodynamic Therapy Combined with PD‐L1 Blockade Boosts Efficacy against Liver Cancer. Advanced Healthcare Materials, 13(7). https://doi.org/10.1002/adhm.202302606

Vancouver

Zhang N, Zeng W, Xu Y, Li R, Wang M, Liu Y, et al. Pyroptosis Induction with Nanosonosensitizer‐Augmented Sonodynamic Therapy Combined with PD‐L1 Blockade Boosts Efficacy against Liver Cancer. Advanced Healthcare Materials. 2024;13(7). doi:10.1002/adhm.202302606

BibTeX
@article{Zhang2024,
  author = {Zhang, Nisi and Zeng, Wenlong and Xu, Yunxue and Li, Rui and Wang, Mengxuan and Liu, Yijia and Qu, Shuai and Ferrara, Katherine W and Dai, Zhifei},
  title = {Pyroptosis Induction with Nanosonosensitizer‐Augmented Sonodynamic Therapy Combined with PD‐L1 Blockade Boosts Efficacy against Liver Cancer},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {7},
  doi = {10.1002/adhm.202302606}
}
Kostenlos starten →